Fingerprint
Dive into the research topics of 'Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically